Activation of the 2-5OAS/RNase L pathway in CVB1 or HAV/18f infected FRhK-4 cells does not require induction of OAS1 or OAS2 expression

Virology

Volumn 388, Issue 1, 2009, Pages 169-184

  Kulka, Michael ^a   Calvo, Mona S ^a   Ngo, Diana T ^a   Wales, Samantha Q ^a   Goswami, Biswendu B ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

2 5A; Antiviral; Coxsackievirus; Hepatitis A virus; Oligoadenylate synthetase; RNase L

Indexed keywords

2' 5' OLIGODENYLATE SYNTHETASE; BETA INTERFERON; ENZYME; OLIGOADENYLATE SYNTHETASE 1; OLIGOADENYLATE SYNTHETASE 2; RIBONUCLEASE L; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS; COXSACKIE VIRUS INFECTION; ENZYME ACTIVATION; ENZYME ACTIVITY; HEPATITIS A; HEPATITIS A VIRUS; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RHESUS MONKEY; RNA CLEAVAGE;

2',5'-OLIGOADENYLATE SYNTHETASE; ANIMALS; CELL LINE; CYTOPATHOGENIC EFFECT, VIRAL; ENDORIBONUCLEASES; ENTEROVIRUS B, HUMAN; ENZYME ACTIVATION; ENZYME INDUCTION; HEPATITIS A VIRUS; INTERFERONS; KIDNEY; MACACA MULATTA; RNA, DOUBLE-STRANDED;

COXSACKIEVIRUS; HEPATITIS A VIRUS;

EID: 67349136468     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.03.014     Document Type: Article

References (84)

1. Anderson D.A. Cytopathology, plaque assay, and heat inactivation of hepatitis A virus strain HM175. J. Med. Virol. 22 (1987) 34-44
2. Barral P.M., Morrison J.M., Drahos J., Gupta P., Sarkar D., Fisher P.B., and Racaniello V.R. MDA-5 is cleaved in poliovirus-infected cells. J. Virol. 81 (2007) 3677-3684
3. Bisbal C., and Silverman R.H. Diverse functions of RNase L and implications in pathology. Biochimie 89 (2007) 789-798
4. Brack K., Frings W., Dotzauer A., and Vallbracht A. A cytopathogenic, apoptosis-inducing variant of hepatitis A virus. J. Virol. 72 (1998) 3370-3376
5. Brack K., Berk I., Magulski T., Lederer J., Dotzauer A., and Vallbracht A. Hepatitis A virus inhibits cellular antiviral defense mechanisms induced by double-stranded RNA. J. Virol. 76 (2002) 11920-11930
6. Castelli J.C., Hassel B.A., Maran A., Paranjape J., Hewitt J.A., Li X.-L., Hsu Y.-T., Silverman R.H., and Youle R.J. The role of 2′-5′ oligoadenylate-activated ribonuclease L in apoptosis. Cell Death Differ. 5 (1988) 313-320
7. Cayley P.J., Knight M., and Kerr I.M. Virus-mediated inhibition of the ppp(A2′p)nA system and its prevention by interferon. Biochem. Biophys. Res. Comm. 104 (1982) 376-382
8. Chebath J., Benech P., Hovanessian A., Galabru J., and Revel M. Four different forms of interferon-induced 2′,5′-oligo(A) synthetase identified by immunoblotting in human cells. J. Biol. Chem. 262 (1987) 3852-3857
9. Chebath J., Benech P., Revel M., and Vigneron M. Constitutive expression of (2′-5′) oligo A synthetase confers resistance to picornavirus infection. Nature 330 (1987) 587-588
10. Chehadeh W., Kerr-Conte J., Pattou F., Alm G., Lefebvre J., Wattre P., and Hober D. Persistent infection of human pancreatic islets by coxsackievirus B is associated with alpha interferon synthesis in β cells. J. Virol. 74 (2000) 10153-10164
11. Conaldi P.G., Serra C., Mossa A., Falconne V., Basolo F., Camussi G., Dolci A., and Toniolo A. Persistent infection of human vascular endothelial cells by group B coxsackieviruses. J. Inf. Diseases 175 (1997) 693-696
12. Cromeans T., Sobsey M.D., and Fields H.A. Development of a plaque assay for a cytopathic, rapidly replicating isolate of hepatitis A virus. J. Med. Virol. 22 (1987) 45-56
13. Cromeans T., Fields H.A., and Sobsey M.D. Replication kinetics and cytopathic effect of hepatitis A virus. J. Gen. Virol. 70 (1989) 2051-2062
14. Daemer R.J., Feinstone S.M., Gust I.D., and Purcell R.H. Propagation of human hepatitis A virus in African green monkey kidney culture: primary isolation and serial passage. Infect. Immun. 32 (1981) 388-393
15. Dotzauer A., Gebhardt U., Bieback K., Gottke U., Kracke A., Mages J., Lemon S.M., and Vallbracht A. Hepatitis A virus-specific immunoglobulin A mediates infection of hepatocytes with hepatitis A virus via asialoglycoprotein receptor. J. Virol. 74 (2000) 10590-10597
16. Fensterl V., Grotheer D., Berk I., Schlemminger S., Vallbracht A., and Dotzauer A. Hepatitis A virus suppresses RIG-I-mediated IRF-3 activation to block induction of beta interferon. J. Virol. 79 (2005) 10968-10977
17. Feuer R., Mena I., Pagarigan R.R., Hassett D.E., and Whitton J.L. Coxsackievirus replication and the cell cycle: a potential regulatory mechanism for viral persistence/latency. Med. Microbiol. Immunol. 193 (2004) 83-90
18. Flodstrom-Tullberg M., Hultcrantz M., Stotland A., Maday A., Tsai D., Fine C., Williams B., Silverman R., and Sarvetnick N. RNase L and double-stranded RNA-dependent protein kinase exert complementary roles in islet cell defense during coxsackievirus infection. J. Immunol. 174 (2005) 1171-1177
19. Geiss G., Jin G., Guo J., Bumgarner R., Katze M.G., and Sen G.C. A comprehensive view of regulation of gene expression by double-stranded RNA-mediated cell signaling. J. Biol. Chem. 276 (2001) 30178-30182
20. Ghosh A., Sarkar S.N., and Sen G.C. Cell growth regulatory and antiviral effects of the p69 isozyme of 2-5(A) synthetase. Virology 266 (2000) 319-328
21. Goswami B.B., and Sharma O.K. Degradation of rRNA in interferon-treated vaccinia virus-infected cells. J. Biol. Chem. 259 (1984) 1371-1374
22. Goswami B.B., Koch W.H., and Cebula T.A. Competitor template RNA for detection and quantitation of hepatitis A virus by PCR. BioTechniques 16 (1994) 114-121
23. Goswami B.B., Kulka M., Ngo D., and Cebula T.A. Apoptosis induced by a cytopathic hepatitis A virus is dependent on caspase activation following ribosomal RNA degradation but occurs in the absence of 2′-5′ oligoadenylate synthetase. Antiviral Res. 63 (2004) 153-166
24. Gribaudo G., Lembo D., Cavallo G., Landolfo S., and Lengyel P. Interferon action: binding of viral RNA to the 40-kilodalton 2′-5′-oligoadenylate synthetase in interferon-treated HeLa cells infected with encephalomyocarditis virus. J. Virol. 65 (1991) 1748-1757
25. Haarmann C.M., Schwimmbeck P.L., Mertens T., Schultheiss H.-P., and Strauer B.E. Identification of serotype-specific and nonserotype-specific B-cell epitopes of coxsackie B virus using synthetic peptides. Virology 200 (1994) 381-389
26. Han J.-Q., and Barton D.J. Activation and evasion of the antiviral 2′-5′ oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA. RNA 8 (2002) 512-525
27. Han J.-Q., Townsend H.L., Jha B.K., Paranjape M., Silvernman R.H., and Barton D.J. A phylogenically conserved RNA structure in the poliovirus open reading frame inhibits the antiviral endoribonuclease RNase L. J. Virol. 81 (2007) 5561-5572
28. Hassel B.A., Zhou A., Sotomayor C., Maran A., and Silverman R.H. A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J. 12 (1993) 3297-3304
29. Heim A., Canu A., Kirschner P., Simon T., Mall G., Hofschneider P.H., and Kandolg R. Synergistic interaction of interferon-beta and interferon-gamma in coxsackievirus B3-infected carrier cultures of human myocardial fibroblasts. J. Infect. Dis. 166 (1992) 958-965
30. Hollinger F.B., and Emerson S.U. Hepatitis A virus. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Straus S.E. (Eds). Fields Virology. 4th ed. vol. 1 (2001), Lippincott Williams and Wilkins, Philadelphia 799-840
31. Hovanessian A.G., and Justesen J. The human 2′-5′oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2′-5′ instead of 3′-5′ phosphodiester bond formation. Biochimie 89 (2007) 779-788
32. Hovanessian A.G., and Kerr I.M. Synthesis of an oligonucleotide inhibitor of protein synthesis in rabbit reticulocyte lysates analogous to that formed in extracts from interferon-treated cells. Eur. J. Biochem. 84 (1978) 149-159
33. Hovanessian A.G., Laurent A.G., Chebath J., Galabru J., Robert N., and Svab J. Identification of 69-kD and 100-kD forms of 2-5A synthetase in interferon treated human cells by specific monoclonal antibodies. EMBO J. 6 (1987) 1273-1280
34. Hovanessian A.G., Svab J., Marie I., Robert N., Chamaret S., and Laurent A.G. Characterization of 69- and 100-kDa forms of 2-5A-synthetase from interferon-treated human cells. J. Biol. Chem. 263 (1988) 4945-4949
35. Hultcrantz M., Huhn M.H., Wolf M., Olsson A., Jacobson S., Williams B.R., Korsgen O., and Flodstrom-Tullberg M. Interferons induce an antiviral state in human pancreatic islet cells. Virology 367 (2007) 92-101
36. Jacobs B.K., and Langland J.O. When two strands are better than one: the modulators of the cellular responses to the double-stranded RNA. Virology 219 (1996) 339-349
37. Justesen J., Hartmann R., and Kjeldgaard N.O. Gene structure and function of the 2′-5′-oligoadenylate synthetase family. Cell Mol. Life Sci. 57 (2000) 1593-1612
38. Kandolf R., Canu A., and Hofschneider P.H. Coxsackie B3 virus can replicate is cultured human foetal heart cells and is inhibited by interferon. J. Mol. Cardiol. 17 (1985) 167-181
39. Kubota K., Nakahara K., Ohtsuka T., Yoshida S., Kawaguchi J., Fujita Y., Ozeki Y., Hara A., Yoshimura C., Furukawa H., Haruyama H., Ichikawa K., Yamashita M., Matsuoka T., and Iijima Y. Identification of 2′-phosphodiesterase, which plays a role in the 2-5A system regulated by interferon. J. Biol. Chem. 279 (2004) 37832-37841
40. Kulka M., Chen A., Ngo D., Bhattacharya S.S., Cebula T.A., and Goswami B.B. The cytopathic 18f strain of hepatitis A virus induces RNA degradation in FRhK-4 cells. Arch. Virol. 148 (2003) 1275-1300
41. Lemon S.L., Murphy P.C., Shields P.A., Ping L.-H., Feinstone S.M., Cromeans T., and Jansen R.W. Antigenic and genetic variation in cytopathic hepatitis A virus variants arising during persistent infection: evidence for genetic recombination. J. Virol. 65 (1991) 2056-2065
42. Marie I., Svab J., and Hovanessian A.G. The binding of the 69- and 100-kDa forms of 2′,5′-oligoadenylate synthetase to different polynucleotides. J. Interferon. Res. 10 (1990) 571-578
43. Marie I., Blanco J., Rebouillat D., and Hovanessian A.G. 69-kDa and 100-kDa isoforms of interferon-induced (2′-5′) oligoadenylate synthetase exhibit differential catalytic parameters. Eur. J. Biochem. 248 (1997) 558-566
44. Miele M.B., Liu D.K., and Kan N.C. Fractionation and characterization of 2′-5′-oligoadenylates by polyacrylamide gel electrophoresis: an alternative method for assaying 2′-5′-oligoadenylate synthetase. J. Interferon. Res. 11 (1991) 33-40
45. Minks M.A., West D.K., Benvin S., and Baglioni C. Structural requirements of double-stranded RNA for the activation of 2′,5′-oligo(A) polymerase and protein kinase of interferon-treated HeLa cells. J. Biol. Chem. 254 (1979) 10180-10183
46. Nakayama T., Urano T., Osano M., Hayashi Y., Sekine S., Ando T., and Makinom S. Outbreak of herpangina associated with coxsackievirus B3 infection. Pediatr. Infect. Dis. J. 8 (1989) 495-498
47. Nasser A.M., and Metcalf T.G. Production of cytopathology in FRhK-4 cells by BS-C-1-passaged hepatitis A virus. Appl. Environ. Microbiol. 53 (1987) 2967-2971
48. Nilsen T.W., Maroney P.A., and Baglioni C. Double-stranded RNA causes synthesis of 2′,5′-oligo(A) and degradation of messenger RNA in interferon-treated cells. J. Biol. Chem. 256 (1981) 7806-7811
49. Nilsen T.W., Maroney P.A., and Baglioni C. Synthesis of (2′-5′) oligoadenylate and activation of an endoribonuclease in interferon-treated HeLa cells infected with reovirus. J. Virol. 42 (1982) 1039-1045
50. Pallansch M.A., and Roos R.P. Enteroviruses: poliovirus, coxsackievirues, echoviruses, and newer enteroviruses. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Straus S.E. (Eds). Fields Virology. 4th ed. vol. 1 (2001), Lippincott Williams and Wilkins, Philadelphia 685-722
51. Player M.R., and Torrence P.F. The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol. Ther 78 (1998) 55-113
52. Racaniello V.R. Picornaviridae: the viruses and their replication. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Straus S.E. (Eds). Fields Virology. 4th ed. vol. 1 (2001), Lippincott Williams and Wilkins, Philadelphia 723-775
53. Rebouillat D., Hovnanian A., Marie I., and Hovanessian A.G. The 100-kDa 2′,5′-oligoadenylate synthetase catalyzing preferentially the synthesis of dimeric pppA2′p5′A molecules is composed of three homologous domains. J. Biol. Chem. 274 (1999) 1557-1565
54. Rebouillat D., Hovnanian A., Gregory D., Hovanessian A.G., and Williams B.R.G. Characterization of the gene encoding the 100-kDa form of human 2′,5′oligoadenylate synthetase. Genomics 70 (2000) 232-240
55. Revel M., Wallach D., Merlin G., Schattner A., Schmidt A., Wolf D., Shulman L., and Kimchi A. Interferon-induced enzymes: microassays and their applications; purification and assay of (2′-5′)-oligoadenylate synthetase and assay of 2′-phosphodiesterase. Methods Enzymol. 79 (1981) 149-161
56. Rice A.P., Roberts W.K., and Kerr I.M. 2-5A accumulates to high levels in interferon-treated, vaccinia virus-infected cells in the absence of any inhibition of virus replication. J. Virol. 50 (1984) 220-228
57. Ross B.C., Anderson D.A., and Gust I.D. Hepatitis A virus and hepatitis A infection. Adv. Virus Res. 39 (1991) 209-253
58. Rusch L., Zhou A., and Silverman R.H. Caspase-dependent apoptosis by 2′,5′-oligoadenylate activation of RNase L is enhanced by IFN-β. J. Interfer. Cyto. Res. 20 (2000) 1091-1100
59. Rysiecki G., Gewert D.R., and Williams B.R.G. Constitutive expression of a 2′,5′-oligoadenylate synthetase cDNA results in increase antiviral activity and growth suppression. J. Interferon. Res. 9 (1989) 649-657
60. Samuel C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 14 (2001) 778-809
61. Sarkar S.N., and Sen G.C. Production, purification, and characterization of recombinant 2′,5′-oligoadenylate synthetases. Methods 15 (1998) 233-242
62. Sarkar S.N., and Sen G.C. Novel functions of proteins encoded by viral stress-inducible genes. Pharmacol. Therapeutics 103 (2004) 245-259
63. Sawai H., Ishibashi K., Itoh M., and Wanatabe S. Radioimmunoassay for 2-5 A using a novel 125I-labeled analog, and analysis of 2-5 A and 2-5 A synthetase activity in human plasma. Prog. Clin. Biol. Res. 202 (1985) 97-104
64. Scherbik S.V., Paranjape J.M., Stockman B.M., Silverman R.H., and Brinton M.A. RNase L plays a role in the antiviral response to west nile virus. J. Virol. 80 (2006) 2987-2999
65. Schnurr D.P., and Schmidt N.J. Persistent infection of mouse fibroblasts with coxsackievirus. Arch. Virol. 81 (1984) 91-101
66. Silverman R.H., Cayley P.J., Knight M., Gilbert C.S., and Kerr I.M. Control of the ppp(A2′p)nA system in HeLa cells, effects of interferon and virus infection. Eur. J. Biochem. 124 (1982) 131-138
67. Silverman R.H., Skehel J.J., James T.C., Wreschner D.H., and Kerr I.M. rRNA cleavage as an index of ppp(A2′p)nA activity in interferon-treated encephalomyocarditis virus-infected cells. J. Virol. 46 (1983) 1051-1055
68. Suhadolnik R.J., Devash Y., Reichenbach N.L., Flick M.B., and Wu J.M. Enzymatic synthesis of the 2′,5′-A4 tetramer analog, 2′,5′-ppp3′dA(p3′dA)3, by rabbit reticulocyte lysates: binding and activation of the 2′,5′-A eta dependent nuclease, hydrolysis of mRNA and inhibitin of protein synthesis. Biochem. Biophys. Res. Commun. 111 (1983) 205-212
69. Takahashi A., Iwasaki Y., Miyaike J., Taniguchi H., Shinomura H., Hanafusa T., Yumoto Y., Moriya A., Koide N., and Tsuji T. Quantitative analysis of p40/46 and p69/71 forms of 2′,5′-oligoadenylate synthetase mRNA by competitive PCR and its clinical application. Clin. Chem. 48 (2002) 1551-1559
70. Townsend H.L., Jha B.K., Han J.-Q., Maluf N.K., Silverman R.H., and Barton D.J. A viral RNA competitively inhibits the antiviral endoribonuclease domain of RNase L. RNA 14 (2008) 1026-1036
71. Vallbracht A., Hofmann L., Wurster K.G., and Flehmig B. Persistent infection of human fibroblasts by hepatitis A virus. J. Gen. Virol. 65 (1984) 609-615
72. Vallbracht A., Gabriel P., Zahn J., and Flehmig B. Hepatitis A virus infection and the interferon system. J. Infect. Dis. 152 (1985) 211-213
73. Venuti A., Di Russo C., del Grosso N., Patti A.-M., Ruggeri F., De Stasio P.R., Martiniello M.G., Pagnotti P., Degener A.M., Midulla M., Pana A., and Perez-Bercoff R. Isolation and molecular cloning of a fast-growing strain of human hepatitis A virus from its double-stranded replicative form. J. Virol. 56 (1985) 579-588
74. Wessely R., Klingel K., Knowlton K.U., and Kandolf R. Cardioselective infection with coxsackievirus B3 requires intact type I interferon signaling. Circulation 103 (2001) 756-761
75. Whitton J.L. Immunopathology during coxsackievirus infection. Semin. Immunopathol. 24 (2002) 201-213
76. Witt P.L., Marie I., Robert N., Irizarry A., Borden E.C., and Hovanessian A.G. Isoforms p69 and p100 of 2′-5′-oligoadenylate synthetaseinduced differentially by interferons in vivo and in vitro. J. Interferon. Res. 13 (1993) 17-23
77. Wreschner D.H., James T.C., Silverman R.H., and Kerr I.M. Ribosomal cleavage, nuclease activation and 2-5A (ppp(A2′p)nA in interferon treated cells. Nucleic Acids Res. 9 (1981) 1571-1581
78. Wu J.M., Wertheimer S.J., Eslami B., Figuereido J.C., and Goswami B.B. Some properties of 2-5A binding/nucleolytic activities in gel filtered rabbit reticulocyte lysates. Biosci. Rep. 5 (1985) 1041-1051
79. Yang Y., Liang Y., Qu L., Chen Z., Yi M., Li K., and Lemon S.M. Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 7253-7258
80. Zaragoza C., Ocampo C.J., Saura M., McMillan A., and Lowenstein C.J. Nitric oxide inhibition of coxsackievirus replication in vitro. J. Clin. Invest. 100 (1997) 1760-1767
81. Zeichhardt J., and Grunert H.-P. Enteroviruses. In: Spector S., Hodinka R.H., and Young S.A. (Eds). Clinical Virology Manual. 3rd ed. (2000), ASM Press, Washington 252-269
82. Zhou A., Paranjape J., Brown T.L., Nie H., Naik C., Dong B., Chang A., Trapp B., Fairchild R., Colmenares C., and Silverman R.H. Interferon action and apoptosis are defective in mice devoid of 2′,5′-oligoadenylate-dependent RNase L. EMBO J. 16 (1997) 6355-6363
83. Zhou A., Paranjape J.M., Hassel B.A., Nie H., Shah S., Galinski B., and Silverman R.H. Impact of RNase L overexpression on viral and cellular growth and death. J. Interferon. Cytokine Res. 18 (1998) 953-961
84. Zhu H., Cong J.-P., Mamtora G., Gingeras T., and Shenk T. Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 14470-14475